Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 26
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo PTEN mutation

  • Bansagi, Boglarka
  • Phan, Vietxuan
  • Baker, Mark R.
  • O'Sullivan, Julia
  • Jennings, Matthew J.
  • Whittaker, Roger G.
  • Müller, Juliane
  • Duff, Jennifer
  • Griffin, Helen
  • Miller, James A.L.
  • Gorman, Grainne S.
  • Lochmüller, Hanns
  • Chinnery, Patrick F.
  • Roos, Andreas
  • Swan, Laura E.
  • Horvath, Rita
Objective: To describe a patient with a multifocal demyelinating motor neuropathy with onset in childhood and a mutation in phosphatase and tensin homolog (PTEN), a tumor suppressor gene associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor, and epilepsy. Functional implications of this protein have been investigated in Parkinson and Alzheimer diseases. Methods: We performed whole-exome sequencing in the patient's genomic DNA validated by Sanger sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic profiling were performed in the patient's fibroblasts. Results: The predominant clinical presentation of the patient was a childhood onset, asymmetric progressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN variant, which was absent in both parents. The pathogenicity of the variant is supported by altered expression of several PTEN-associated proteins involved in tumorigenesis. Moreover, fibroblasts showed a defect in catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate. In support of our findings, focal hypermyelination leading to peripheral neuropathy has been reported in PTEN-deficient mice. Conclusion: We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy with a skin hamartoma syndrome. A similar mechanism may potentially underlie other forms of Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway., R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), and the European Research Council (309548). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 305444 (RD-Connect) and 305121 (Neuromics), from the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and from the Newton Fund (UK/Turkey, MR/N027302/1). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. A.R. received financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin and the Bundesministerium für Bildung und Forschung. L.E.S. was supported by Wellcome Trust (105616/Z/14/Z) and the Medical Research Council (MRC/N010035/1).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

  • Signorelli, Mirko
  • Ayoglu, Burcu
  • Johansson, Camilla
  • Lochmüller, Hanns
  • Straub, Volker
  • Muntoni, Francesco
  • Niks, Erik
  • Tsonaka, Roula
  • Persson, Anja
  • Aartsma-Rus, Annemieke
  • Nilsson, Peter
  • Al-Khalili Szigyarto, Cristina
  • Spitali, Pietro
BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter-individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly needed to improve clinical trial design and facilitate drug development. METHODS: In this study, we aimed to appraise the value of protein biomarkers to predict prognosis and monitor disease progression or treatment outcome in patients affected by DMD. We collected clinical data and 303 blood samples from 157 DMD patients in three clinical centres; 78 patients contributed multiple blood samples over time, with a median follow-up time of 2 years. We employed linear mixed models to identify biomarkers that are associated with disease progression, wheelchair dependency, and treatment with corticosteroids and performed survival analysis to find biomarkers whose levels are associated with time to loss of ambulation. RESULTS: Our analysis led to the identification of 21 proteins whose levels significantly decrease with age and nine proteins whose levels significantly increase. Seven of these proteins are also differentially expressed in non-ambulant patients, and three proteins are differentially expressed in patients treated with glucocorticosteroids. Treatment with corticosteroids was found to partly counteract the effect of disease progression on two biomarkers, namely, malate dehydrogenase 2 (MDH2, P = 0.0003) and ankyrin repeat domain 2 (P = 0.0005); however, patients treated with corticosteroids experienced a further reduction on collagen 1 serum levels (P = 0.0003), especially following administration of deflazacort. A time to event analysis allowed to further support the use of MDH2 as a prognostic biomarker as it was associated with an increased risk of wheelchair dependence (P = 0.0003). The obtained data support the prospective evaluation of the identified biomarkers in natural history and clinical trials as exploratory biomarkers. CONCLUSIONS: We identified a number of serum biomarkers associated with disease progression, loss of ambulation, and treatment with corticosteroids. The identified biomarkers are promising candidate prognostic and surrogate biomarkers, which may support drug developers if confirmed in prospective studies. The serum levels of MDH2 are of particular interest, as they correlate with disease stage and response to treatment with corticosteroids, and are also associated with the risk of wheelchair dependency and pulmonary function., We acknowledge the Association Française Contre les Myopathies (grant no. 17724) and the Stichting Duchenne Parent Project for funding this work. We thank all members of the Affinity Proteomics group at SciLifeLab for technical assistance, as well as Prof. Mathias Uhlén and the entire staff of the Human Protein Atlas for their efforts. H.L. received funding by the Medical Research Council (MRC) Centre for Neuromuscular Diseases UK (reference G1002274 and grant ID 98482) and by the European Commission through the projects Neuromics (no. 305121) and RD‐Connect (no. 305444). The authors thank the MRC Centre for Neuromuscular Diseases for its support through the Neuromuscular Disease BioBank and the Muscular Dystrophy UK for its support to the Neuromuscular Centre at UCL. F.M. is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre; the views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons

  • Boczonadi, Veronika
  • Meyer, Kathrin
  • Gonczarowska-Jorge, Humberto
  • Griffin, Helen
  • Roos, Andreas
  • Bartsakoulia, Marina
  • Bansagi, Boglarka
  • Ricci, Giulia
  • Palinkas, Fanni
  • Zahedi, René P.
  • Bruni, Francesco
  • Kaspar, Brian
  • Lochmüller, Hanns
  • Boycott, Kym M.
  • Müller, Juliane
  • Horvath, Rita
The nuclear-encoded glycyl-tRNA synthetase gene (GARS) is essential for protein translation in both cytoplasm and mitochondria. In contrast, different genes encode the mitochondrial and cytosolic forms of most other tRNA synthetases. Dominant GARS mutations were described in inherited neuropathies, while recessive mutations cause severe childhood-onset disorders affecting skeletal muscle and heart. The downstream events explaining tissue-specific phenotype-genotype relations remained unclear. We investigated the mitochondrial function of GARS in human cell lines and in the GarsC210R mouse model. Human-induced neuronal progenitor cells (iNPCs) carrying dominant and recessive GARS mutations showed alterations of mitochondrial proteins, which were more prominent in iNPCs with dominant, neuropathy-causing mutations. Although comparative proteomic analysis of iNPCs showed significant changes in mitochondrial respiratory chain complex subunits, assembly genes, Krebs cycle enzymes and transport proteins in both recessive and dominant mutations, proteins involved in fatty acid oxidation were only altered by recessive mutations causing mitochondrial cardiomyopathy. In contrast, significant alterations of the vesicle-associated membrane protein-associated protein B (VAPB) and its downstream pathways such as mitochondrial calcium uptake and autophagy were detected in dominant GARS mutations. The role of VAPB has been supported by similar results in the GarsC210R mice. Our data suggest that altered mitochondria-associated endoplasmic reticulum (ER) membranes (MAM) may be important disease mechanisms leading to neuropathy in this condition., R.H. is a Wellcome Investigator (109915/Z/15/Z) supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Mitochondrial European Educational Training (MEET), ITN MARIE CURIE PEOPLE, (317433). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect), 305121 (Neuromics), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). H.J.G., A.R. and R.P.Z. acknowledge the financial support by the Ministeriumfür Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the SenatsverwaltungfürWirtschaft, Technologie und Forschung des Landes Berlin, and the BundesministeriumfürBildung und Forschung. H.G.J. further thanks the CAPES Foundation for financial support.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

GNE myopathy: from clinics and genetics to pathology and research strategies

  • Pogoryelova, Oksana
  • González Coraspe, José Andrés
  • Nikolenko, Nikoletta
  • Lochmüller, Hanns
  • Roos, Andreas
GNE myopathy is an ultra-rare autosomal recessive disease, which starts as a distal muscle weakness and ultimately leads to a wheelchair bound state. Molecular research and animal modelling significantly moved forward understanding of GNE myopathy mechanisms and suggested therapeutic interventions to alleviate the symptoms. Multiple therapeutic attempts are being made to supplement sialic acid depleted in GNE myopathy muscle cells. Translational research field provided valuable knowledge through natural history studies, patient registries and clinical trial, which significantly contributed to bringing forward an era of GNE myopathy treatment. In this review, we are summarising current GNE myopathy, scientific trends and open questions, which would be of significant interest for a wide neuromuscular diseases community., We gratefully acknowledge the financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen. Work by the authors has been supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics). This work was further supported by a grant from the DGM (Deutsche Gesellschaft für Muskelkranke).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice

  • Issop, Yasmin
  • Hathazi, Denisa
  • Khan, Muzamil Majid
  • Rudolf, Rüdiger
  • Weis, Joachim
  • Spendiff, Sally
  • Slater, Clarke R.
  • Roos, Andreas
  • Lochmüller, Hanns
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the rate-limiting enzyme in the hexosamine biosynthetic pathway which yields precursors required for protein and lipid glycosylation. Mutations in GFPT1 and other genes downstream of this pathway cause congenital myasthenic syndrome (CMS) characterized by fatigable muscle weakness owing to impaired neurotransmission. The precise pathomechanisms at the neuromuscular junction (NMJ) owing to a deficiency in GFPT1 is yet to be discovered. One of the challenges we face is the viability of Gfpt1-/- knockout mice. In this study, we use Cre/LoxP technology to generate a muscle-specific GFPT1 knockout mouse model, Gfpt1tm1d/tm1d, characteristic of the human CMS phenotype. Our data suggest a critical role for muscle derived GFPT1 in the development of the NMJ, neurotransmission, skeletal muscle integrity and highlight that a deficiency in skeletal muscle alone is sufficient to cause morphological postsynaptic NMJ changes that are accompanied by presynaptic alterations despite the conservation of neuronal GFPT1 expression. In addition to the conventional morphological NMJ changes and fatigable muscle weakness, Gfpt1tm1d/tm1d mice display a progressive myopathic phenotype with the presence of tubular aggregates in muscle, characteristic of the GFPT1-CMS phenotype. We further identify an upregulation of skeletal muscle proteins glypican-1, farnesyltransferase/geranylgeranyltransferase type-1 subunit α and muscle-specific kinase, which are known to be involved in the differentiation and maintenance of the NMJ. The Gfpt1tm1d/tm1d model allows for further investigation of pathophysiological consequences on genes and pathways downstream of GFPT1 likely to involve misglycosylation or hypoglycosylation of NMJs and muscle targets., This work was supported by a studentship of The Barbour Foundation and the Medical Research Council (UK) to Y.I.; the Medical Research Council as part of the MRC Centre for Neuromuscular Diseases (reference G1002274, grant ID 98482), a Wellcome Trust Pathfinder Award (201064/Z/16/Z) to H.L.; the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics) to H.L.; an award from the French Muscular Dystrophy Association (AFM-Téléthon) No. 20870 to H.L.; the German Research Fund (RU923/8-2) to R.R., and by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin, and the Bundesministerium für Bildung und Forschung. Funding to pay the Open Access publication charges for this article was provided by The Medical Research Council (MRC).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Molecular pathophysiology of human MICU1 deficiency

  • Kohlschmidt, Nicolai
  • Elbracht, Miriam
  • Czech, Artur
  • Häusler, Martin
  • Phan, Vietxuan
  • Töpf, Ana
  • Huang, Kai-Ting
  • Bartok, Adam
  • Eggermann, Katja
  • Zippel, Stephanie
  • Eggermann, Thomas
  • Freier, Erik
  • Groß, Claudia
  • Lochmüller, Hanns
  • Horvath, Rita
  • Hajnóczky, György
  • Weis, Joachim
  • Roos, Andreas
Aims: MICU1 encodes the gatekeeper of the mitochondrial Ca2+ uniporter, MICU1 and biallelic loss-of-function mutations cause a complex, neuromuscular disorder in children. Although the role of the protein is well understood, the precise molecular pathophysiology leading to this neuropaediatric phenotype has not been fully elucidated. Here we aimed to obtain novel insights into MICU1 pathophysiology. Methods: Molecular genetic studies along with proteomic profiling, electron-, light- and Coherent anti-Stokes Raman scattering microscopy and immuno-based studies of protein abundances and Ca2+ transport studies were employed to examine the pathophysiology of MICU1 deficiency in humans. Results: We describe two patients carrying MICU1 mutations, two nonsense (c.52C>T; p.(Arg18*) and c.553C>T; p.(Arg185*)) and an intragenic exon 2-deletion presenting with ataxia, developmental delay and early onset myopathy, clinodactyly, attention deficits, insomnia and impaired cognitive pain perception. Muscle biopsies revealed signs of dystrophy and neurogenic atrophy, severe mitochondrial perturbations, altered Golgi structure, vacuoles and altered lipid homeostasis. Comparative mitochondrial Ca2+ transport and proteomic studies on lymphoblastoid cells revealed that the [Ca2+ ] threshold and the cooperative activation of mitochondrial Ca2+ uptake were lost in MICU1-deficient cells and that 39 proteins were altered in abundance. Several of those proteins are linked to mitochondrial dysfunction and/or perturbed Ca2+ homeostasis, also impacting on regular cytoskeleton (affecting Spectrin) and Golgi architecture, as well as cellular survival mechanisms. Conclusions: Our findings (i) link dysregulation of mitochondrial Ca2+ uptake with muscle pathology (including perturbed lipid homeostasis and ER-Golgi morphology), (ii) support the concept of a functional interplay of ER-Golgi and mitochondria in lipid homeostasis and (iii) reveal the vulnerability of the cellular proteome as part of the MICU1-related pathophysiology., This study was supported by the ‘Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen’, the ‘Regierenden Bürgermeister von Berlin - Senatskanzlei Wissenschaft und Forschung’ and the ‘Bundesministerium für Bildung und Forschung’, also in form of the Leibniz-Research-Cluster (grant number: 031A360E). This work was also supported by a grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR and by an NIH grant (RO1 GM102724) to GH. The research leading to these results has also received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 2012-305121 ‘Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)’. RH is a Wellcome Investigator (109915/Z/15/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Newton Fund (MR/N027302/1). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412) and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279)
Repisalud
Publication Artículo científico (JournalArticle)

Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity

  • Matalonga, Leslie
  • Laurie, Steven
  • Papakonstantinou, Anastasios
  • Piscia, Davide
  • Mereu, Elisabetta
  • Bullich, Gemma
  • Thompson, Rachel
  • Horvath, Rita
  • Pérez-Jurado, Luis Alberto
  • Riess, Olaf
  • Gut, Ivo
  • van Ommen, Gert-Jan
  • Lochmüller, Hanns
  • Beltran, Sergi
  • RD–Connect Genome-Phenome Analysis Platform
  • URD-Cat Data Contributors
  • Posada De la Paz, Manuel
Autozygosity is associated with an increased risk of genetic rare disease, thus being a relevant factor for clinical genetic studies. More than 2400 exome sequencing data sets were analyzed and screened for autozygosity on the basis of detection of >1 Mbp runs of homozygosity (ROHs). A model was built to predict if an individual is likely to be a consanguineous offspring (accuracy, 98%), and probability of consanguinity ranges were established according to the total ROH size. Application of the model resulted in the reclassification of the consanguinity status of 12% of the patients. The analysis of a subset of 79 consanguineous cases with the Rare Disease (RD)-Connect Genome-Phenome Analysis Platform, combining variant filtering and homozygosity mapping, enabled a 50% reduction in the number of candidate variants and the identification of homozygous pathogenic variants in 41 patients, with an overall diagnostic yield of 52%. The newly defined consanguinity ranges provide, for the first time, specific ROH thresholds to estimate inbreeding within a pedigree on disparate exome sequencing data, enabling confirmation or (re)classification of consanguineous status, hence increasing the efficiency of molecular diagnosis and reporting on secondary consanguinity findings, as recommended by American College of Medical Genetics and Genomics guidelines.
Repisalud
Publication Artículo científico (JournalArticle)

Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database

  • Koeks, Zaïda
  • Bladen, Catherine L
  • Salgado, David
  • van Zwet, Erik
  • Pogoryelova, Oksana
  • McMacken, Grace
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Bellgard, Matthew I
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Herczegfalvi, Agnes
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Ferlini, Alessandra
  • Kimura, En
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Klein, Andrea
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Oznur, Tunca
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Béroud, Christophe
  • Verschuuren, Jan J
  • Lochmüller, Hanns
Background: Recent short-term clinical trials in patients with Duchenne Muscular Dystrophy (DMD) have indicated greater disease variability in terms of progression than expected. In addition, as average life-expectancy increases, reliable data is required on clinical progression in the older DMD population. Objective: To determine the effects of corticosteroids on major clinical outcomes of DMD in a large multinational cohort of genetically confirmed DMD patients. Methods: In this cross-sectional study we analysed clinical data from 5345 genetically confirmed DMD patients from 31 countries held within the TREAT-NMD global DMD database. For analysis patients were categorised by corticosteroid background and further stratified by age. Results: Loss of ambulation in non-steroid treated patients was 10 years and in corticosteroid treated patients 13 years old (p = 0.0001). Corticosteroid treated patients were less likely to need scoliosis surgery (p < 0.001) or ventilatory support (p < 0.001) and there was a mild cardioprotective effect of corticosteroids in the patient population aged 20 years and older (p = 0.0035). Patients with a single deletion of exon 45 showed an increased survival in contrast to other single exon deletions. Conclusions: This study provides data on clinical outcomes of DMD across many healthcare settings and including a sizeable cohort of older patients. Our data confirm the benefits of corticosteroid treatment on ambulation, need for scoliosis surgery, ventilation and, to a lesser extent, cardiomyopathy. This study underlines the importance of data collection via patient registries and the critical role of multi-centre collaboration in the rare disease field.
Repisalud
Publication Artículo científico (JournalArticle)

The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations

  • Bladen, Catherine L
  • Salgado, David
  • Monges, Soledad
  • Foncuberta, Maria E
  • Kekou, Kyriaki
  • Kosma, Konstantina
  • Dawkins, Hugh
  • Lamont, Leanne
  • Roy, Anna J
  • Chamova, Teodora
  • Guergueltcheva, Velina
  • Chan, Sophelia
  • Korngut, Lawrence
  • Campbell, Craig
  • Dai, Yi
  • Wang, Jen
  • Barišić, Nina
  • Brabec, Petr
  • Lähdetie, Jaana
  • Walter, Maggie C
  • Schreiber-Katz, Olivia
  • Karcagi, Veronika
  • Garami, Marta
  • Viswanathan, Venkatarman
  • Bayat, Farhad
  • Buccella, Filippo
  • Kimura, En
  • Koeks, Zaïda
  • van den Bergen, Janneke C
  • Rodrigues, Miriam
  • Roxburgh, Richard
  • Lusakowska, Anna
  • Kostera-Pruszczyk, Anna
  • Zimowski, Janusz
  • Santos, Rosário
  • Neagu, Elena
  • Artemieva, Svetlana
  • Rasic, Vedrana Milic
  • Vojinovic, Dina
  • Posada De la Paz, Manuel
  • Bloetzer, Clemens
  • Jeannet, Pierre-Yves
  • Joncourt, Franziska
  • Díaz-Manera, Jordi
  • Gallardo, Eduard
  • Karaduman, A Ayşe
  • Topaloğlu, Haluk
  • El Sherif, Rasha
  • Stringer, Angela
  • Shatillo, Andriy V
  • Martin, Ann S
  • Peay, Holly L
  • Bellgard, Matthew I
  • Kirschner, Jan
  • Flanigan, Kevin M
  • Straub, Volker
  • Bushby, Kate
  • Verschuuren, Jan
  • Aartsma-Rus, Annemieke
  • Béroud, Christophe
  • Lochmüller, Hanns
Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (http://umd.be/TREAT_DMD/). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).
Repisalud
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernández-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raul
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Rémi
  • Alonso, Angel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J
  • Cañada-Pallarés, Andrés
  • Fernández, José M
  • Hansson, Mats G
  • Horvath, Rita
  • Jacobsen, Julius O B
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • Lopez-Martin, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis Alberto
  • Posada De la Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • 't Hoen, Peter A C
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo G
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes.
Repisalud
Publication Artículo científico (JournalArticle)

Improving the informed consent process in international collaborative rare disease research: effective consent for effective research

  • Gainotti, Sabina
  • Turner, Cathy
  • Woods, Simon
  • Kole, Anna
  • McCormack, Pauline
  • Lochmüller, Hanns
  • Riess, Olaf
  • Straub, Volker
  • Posada De la Paz, Manuel
  • Taruscio, Domenica
  • Mascalzoni, Deborah
The increased international sharing of data in research consortia and the introduction of new technologies for sequencing challenge the informed consent (IC) process, adding complexities that require coordination between research centres worldwide. Rare disease consortia present special challenges since available data and samples may be very limited. Thus, it is especially relevant to ensure the best use of available resources but at the same time protect patients' right to integrity. To achieve this aim, there is an ethical duty to plan in advance the best possible consent procedure in order to address possible ethical and legal hurdles that could hamper research in the future. Therefore, it is especially important to identify key core elements (CEs) to be addressed in the IC documents for international collaborative research in two different situations: (1) new research collections (biobanks and registries) for which information documents can be created according to current guidelines and (2) established collections obtained without IC or with a previous consent that does not cover all CEs. We propose here a strategy to deal with consent in these situations. The principles have been applied and are in current practice within the RD-Connect consortia - a global research infrastructure funded by the European Commission Seventh Framework program but forward looking in terms of issues addressed. However, the principles established, the lessons learned and the implications for future research are of direct relevance to all internationally collaborative rare-disease projects.
Repisalud
Publication Artículo científico (JournalArticle)

The risk of re-identification versus the need to identify individuals in rare disease research

  • Hansson, Mats G
  • Lochmüller, Hanns
  • Riess, Olaf
  • Schaefer, Franz
  • Orth, Michael
  • Rubinstein, Yaffa
  • Molster, Caron
  • Dawkins, Hugh
  • Taruscio, Domenica
  • Posada De la Paz, Manuel
  • Woods, Simon
There is a growing concern in the ethics literature and among policy makers that de-identification or coding of personal data and biospecimens is not sufficient for protecting research subjects from privacy invasions and possible breaches of confidentiality due to the possibility of unauthorized re-identification. At the same time, there is a need in medical science to be able to identify individual patients. In particular for rare disease research there is a special and well-documented need for research collaboration so that data and biosamples from multiple independent studies can be shared across borders. In this article, we identify the needs and arguments related to de-identification and re-identification of patients and research subjects and suggest how the different needs may be balanced within a framework of using unique encrypted identifiers.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Current trends in biobanking for rare diseases: a review

  • Graham, Caroline E
  • Molster, Caron
  • Baynam, Gareth
  • Bushby, Kate
  • Hansson, Mats
  • Kole, Anna
  • Mora, Marina
  • Monaco, Lucia
  • Bellgard, Matthew I
  • Carpentieri, David
  • Posada De la Paz, Manuel
  • Riess, Olaf
  • Rubinstein, Yaffa R
  • Schaefer, Franz
  • Taruscio, Domenica
  • Terry, Sharon F
  • Zatloukal, Kurt
  • Knoppers, Bartha
  • Lochmüller, Hanns
  • Dawkins, Hugh
Rare diseases (RD) refer to a collection of approximately 5,000–8,000 individual diseases that have a low prevalence and are often genetic in origin. While RD can manifest throughout life, they frequently affect children and newborns. Common characteristics include being severe, disabling, life-threatening, degenerative and affecting different organ systems. The burden of RD is often exacerbated by a lack of specific treatments. Whilst there is etiological heterogeneity, there is overlap in cellular and molecular pathways. Amongst specialists, there is legitimate hope that based on genetic knowledge and pathway definition, a new medical classification system, currently called “precision medicine”, will be developed, which may change our view on how to apply shared therapeutic targets. Thus, collection of clinical and genetic data and biospecimens (in biobanks) will play an increasing role in diagnoses and development of therapies for RD. Biobanks are maintained collaboratively by researchers or their institutions, and involve a delicate balance between health policy objectives, academic research, public good outcomes, and community trust. Due to the nature of RD, international cooperation is critical for sharing limited numbers of RD samples and achieving a critical mass. Here we review the current and future direction of RD biobanks and discuss research and development stemming from the use of biospecimens to improve management of RD.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Molecular pathophysiology of human MICU1 deficiency

  • Kohlschmidt, Nicolai
  • Elbracht, Miriam
  • Czech, Artur
  • Häusler, Martin
  • Phan, Vietxuan
  • Töpf, Ana
  • Huang, Kai-Ting
  • Bartok, Adam
  • Eggermann, Katja
  • Zippel, Stephanie
  • Eggermann, Thomas
  • Freier, Erik
  • Groß, Claudia
  • Lochmüller, Hanns
  • Horvath, Rita
  • Hajnóczky, György
  • Weis, Joachim
  • Roos, Andreas
Aims: MICU1 encodes the gatekeeper of the mitochondrial Ca2+ uniporter, MICU1 and biallelic loss-of-function mutations cause a complex, neuromuscular disorder in children. Although the role of the protein is well understood, the precise molecular pathophysiology leading to this neuropaediatric phenotype has not been fully elucidated. Here we aimed to obtain novel insights into MICU1 pathophysiology. Methods: Molecular genetic studies along with proteomic profiling, electron-, light- and Coherent anti-Stokes Raman scattering microscopy and immuno-based studies of protein abundances and Ca2+ transport studies were employed to examine the pathophysiology of MICU1 deficiency in humans. Results: We describe two patients carrying MICU1 mutations, two nonsense (c.52C>T; p.(Arg18*) and c.553C>T; p.(Arg185*)) and an intragenic exon 2-deletion presenting with ataxia, developmental delay and early onset myopathy, clinodactyly, attention deficits, insomnia and impaired cognitive pain perception. Muscle biopsies revealed signs of dystrophy and neurogenic atrophy, severe mitochondrial perturbations, altered Golgi structure, vacuoles and altered lipid homeostasis. Comparative mitochondrial Ca2+ transport and proteomic studies on lymphoblastoid cells revealed that the [Ca2+ ] threshold and the cooperative activation of mitochondrial Ca2+ uptake were lost in MICU1-deficient cells and that 39 proteins were altered in abundance. Several of those proteins are linked to mitochondrial dysfunction and/or perturbed Ca2+ homeostasis, also impacting on regular cytoskeleton (affecting Spectrin) and Golgi architecture, as well as cellular survival mechanisms. Conclusions: Our findings (i) link dysregulation of mitochondrial Ca2+ uptake with muscle pathology (including perturbed lipid homeostasis and ER-Golgi morphology), (ii) support the concept of a functional interplay of ER-Golgi and mitochondria in lipid homeostasis and (iii) reveal the vulnerability of the cellular proteome as part of the MICU1-related pathophysiology., This study was supported by the ‘Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen’, the ‘Regierenden Bürgermeister von Berlin - Senatskanzlei Wissenschaft und Forschung’ and the ‘Bundesministerium für Bildung und Forschung’, also in form of the Leibniz-Research-Cluster (grant number: 031A360E). This work was also supported by a grant of the French Muscular Dystrophy Association (AFM-Téléthon) (#21466) to AR and by an NIH grant (RO1 GM102724) to GH. The research leading to these results has also received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 2012-305121 ‘Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)’. RH is a Wellcome Investigator (109915/Z/15/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Newton Fund (MR/N027302/1). HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412) and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice

  • Issop, Yasmin
  • Hathazi, Denisa
  • Khan, Muzamil Majid
  • Rudolf, Rüdiger
  • Weis, Joachim
  • Spendiff, Sally
  • Slater, Clarke R.
  • Roos, Andreas
  • Lochmüller, Hanns
Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the rate-limiting enzyme in the hexosamine biosynthetic pathway which yields precursors required for protein and lipid glycosylation. Mutations in GFPT1 and other genes downstream of this pathway cause congenital myasthenic syndrome (CMS) characterized by fatigable muscle weakness owing to impaired neurotransmission. The precise pathomechanisms at the neuromuscular junction (NMJ) owing to a deficiency in GFPT1 is yet to be discovered. One of the challenges we face is the viability of Gfpt1-/- knockout mice. In this study, we use Cre/LoxP technology to generate a muscle-specific GFPT1 knockout mouse model, Gfpt1tm1d/tm1d, characteristic of the human CMS phenotype. Our data suggest a critical role for muscle derived GFPT1 in the development of the NMJ, neurotransmission, skeletal muscle integrity and highlight that a deficiency in skeletal muscle alone is sufficient to cause morphological postsynaptic NMJ changes that are accompanied by presynaptic alterations despite the conservation of neuronal GFPT1 expression. In addition to the conventional morphological NMJ changes and fatigable muscle weakness, Gfpt1tm1d/tm1d mice display a progressive myopathic phenotype with the presence of tubular aggregates in muscle, characteristic of the GFPT1-CMS phenotype. We further identify an upregulation of skeletal muscle proteins glypican-1, farnesyltransferase/geranylgeranyltransferase type-1 subunit α and muscle-specific kinase, which are known to be involved in the differentiation and maintenance of the NMJ. The Gfpt1tm1d/tm1d model allows for further investigation of pathophysiological consequences on genes and pathways downstream of GFPT1 likely to involve misglycosylation or hypoglycosylation of NMJs and muscle targets., This work was supported by a studentship of The Barbour Foundation and the Medical Research Council (UK) to Y.I.; the Medical Research Council as part of the MRC Centre for Neuromuscular Diseases (reference G1002274, grant ID 98482), a Wellcome Trust Pathfinder Award (201064/Z/16/Z) to H.L.; the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics) to H.L.; an award from the French Muscular Dystrophy Association (AFM-Téléthon) No. 20870 to H.L.; the German Research Fund (RU923/8-2) to R.R., and by the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin, and the Bundesministerium für Bildung und Forschung. Funding to pay the Open Access publication charges for this article was provided by The Medical Research Council (MRC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven, 1973-
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvò, Alberto
  • Fernández Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles, 1987-
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Tonda, Raúl
  • Bayés, Mònica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean-Remi
  • Pérez Jurado, Luis Alberto
  • Rambla de Argila, Jordi
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltran, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., We acknowledge the support of the developers of PhenoTips, which was used in the past by RD-Connect and NeurOmics as the primary tool to collate phenotypic data. We would also like to thank the leaders and members of the Instituto Nacional de Bioinformática (INB) and ELIXIR for their support and collaboration throughout the years. RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increasing phenotypic annotation improves the diagnostic rate of exome sequencing in a rare neuromuscular disorder

  • Thompson, Rachel
  • Papakonstantinou, Anastasios
  • Beltran, Sergi
  • Topf, Ana
  • de Paula Estephan, Eduardo
  • Poloavarapu, Kiran
  • Hoen, Peter A. C.
  • Missier, Paolo
  • Lochmüller, Hanns
Phenotype-based filtering and prioritization contribute to the interpretation of genetic variants detected in exome sequencing. However, it is currently unclear how extensive this phenotypic annotation should be. In this study, we compare methods for incorporating phenotype into the interpretation process and assess the extent to which phenotypic annotation aids prioritization of the correct variant. Using a cohort of 29 patients with congenital myasthenic syndromes with causative variants in known or newly discovered disease genes, exome data and the Human Phenotype Ontology (HPO)-coded phenotypic profiles, we show that gene-list filters created from phenotypic annotations perform similarly to curated disease-gene virtual panels. We use Exomiser, a prioritization tool incorporating phenotypic comparisons, to rank candidate variants while varying phenotypic annotation. Analyzing 3,712 combinations, we show that increasing phenotypic annotation improved prioritization of the causative variant, from 62% ranked first on variant alone to 90% with seven HPO annotations. We conclude that any HPO-based phenotypic annotation aids variant discovery and that annotation with over five terms is recommended in our context. Although focused on a constrained cohort, this provides real-world validation of the utility of phenotypic annotation for variant prioritization. Further research is needed to extend this concept to other diseases and more diverse cohorts., Data was analyzed using the RD‐Connect Genome‐Phenome Analysis Platform developed under the 2012‐2018 FP7‐funded project RD‐ Connect (Grant Agreement No.: 305444). R. T., S. B., A. P. N., P. tH., and H. L. received support from the EU FP7 projects 305444 (RD‐ Connect) and 305121 (NeurOmics). S. B. received support from the EU FP7 project 313010 (BBMRI‐LPC). S. B. and P. tH. received support from the EU Horizon 2020 project 779257 (Solve‐RD). S. B., P. tH., and H. L. received support from the EU Horizon 2020 project 825575 (EJP‐RD). H. L. is supported by a project grant of the Canadian Institutes of Health Research (CIHR PJT 162265)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

  • Signorelli, Mirko
  • Ayoglu, Burcu
  • Johansson, Camilla
  • Lochmüller, Hanns
  • Straub, Volker
  • Muntoni, Francesco
  • Niks, Erik
  • Tsonaka, Roula
  • Persson, Anja
  • Aartsma-Rus, Annemieke
  • Nilsson, Peter
  • Al-Khalili Szigyarto, Cristina
  • Spitali, Pietro
BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter-individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly needed to improve clinical trial design and facilitate drug development. METHODS: In this study, we aimed to appraise the value of protein biomarkers to predict prognosis and monitor disease progression or treatment outcome in patients affected by DMD. We collected clinical data and 303 blood samples from 157 DMD patients in three clinical centres; 78 patients contributed multiple blood samples over time, with a median follow-up time of 2 years. We employed linear mixed models to identify biomarkers that are associated with disease progression, wheelchair dependency, and treatment with corticosteroids and performed survival analysis to find biomarkers whose levels are associated with time to loss of ambulation. RESULTS: Our analysis led to the identification of 21 proteins whose levels significantly decrease with age and nine proteins whose levels significantly increase. Seven of these proteins are also differentially expressed in non-ambulant patients, and three proteins are differentially expressed in patients treated with glucocorticosteroids. Treatment with corticosteroids was found to partly counteract the effect of disease progression on two biomarkers, namely, malate dehydrogenase 2 (MDH2, P = 0.0003) and ankyrin repeat domain 2 (P = 0.0005); however, patients treated with corticosteroids experienced a further reduction on collagen 1 serum levels (P = 0.0003), especially following administration of deflazacort. A time to event analysis allowed to further support the use of MDH2 as a prognostic biomarker as it was associated with an increased risk of wheelchair dependence (P = 0.0003). The obtained data support the prospective evaluation of the identified biomarkers in natural history and clinical trials as exploratory biomarkers. CONCLUSIONS: We identified a number of serum biomarkers associated with disease progression, loss of ambulation, and treatment with corticosteroids. The identified biomarkers are promising candidate prognostic and surrogate biomarkers, which may support drug developers if confirmed in prospective studies. The serum levels of MDH2 are of particular interest, as they correlate with disease stage and response to treatment with corticosteroids, and are also associated with the risk of wheelchair dependency and pulmonary function., We acknowledge the Association Française Contre les Myopathies (grant no. 17724) and the Stichting Duchenne Parent Project for funding this work. We thank all members of the Affinity Proteomics group at SciLifeLab for technical assistance, as well as Prof. Mathias Uhlén and the entire staff of the Human Protein Atlas for their efforts. H.L. received funding by the Medical Research Council (MRC) Centre for Neuromuscular Diseases UK (reference G1002274 and grant ID 98482) and by the European Commission through the projects Neuromics (no. 305121) and RD‐Connect (no. 305444). The authors thank the MRC Centre for Neuromuscular Diseases for its support through the Neuromuscular Disease BioBank and the Muscular Dystrophy UK for its support to the Neuromuscular Centre at UCL. F.M. is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre; the views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons

  • Boczonadi, Veronika
  • Meyer, Kathrin
  • Gonczarowska-Jorge, Humberto
  • Griffin, Helen
  • Roos, Andreas
  • Bartsakoulia, Marina
  • Bansagi, Boglarka
  • Ricci, Giulia
  • Palinkas, Fanni
  • Zahedi, René P.
  • Bruni, Francesco
  • Kaspar, Brian
  • Lochmüller, Hanns
  • Boycott, Kym M.
  • Müller, Juliane
  • Horvath, Rita
The nuclear-encoded glycyl-tRNA synthetase gene (GARS) is essential for protein translation in both cytoplasm and mitochondria. In contrast, different genes encode the mitochondrial and cytosolic forms of most other tRNA synthetases. Dominant GARS mutations were described in inherited neuropathies, while recessive mutations cause severe childhood-onset disorders affecting skeletal muscle and heart. The downstream events explaining tissue-specific phenotype-genotype relations remained unclear. We investigated the mitochondrial function of GARS in human cell lines and in the GarsC210R mouse model. Human-induced neuronal progenitor cells (iNPCs) carrying dominant and recessive GARS mutations showed alterations of mitochondrial proteins, which were more prominent in iNPCs with dominant, neuropathy-causing mutations. Although comparative proteomic analysis of iNPCs showed significant changes in mitochondrial respiratory chain complex subunits, assembly genes, Krebs cycle enzymes and transport proteins in both recessive and dominant mutations, proteins involved in fatty acid oxidation were only altered by recessive mutations causing mitochondrial cardiomyopathy. In contrast, significant alterations of the vesicle-associated membrane protein-associated protein B (VAPB) and its downstream pathways such as mitochondrial calcium uptake and autophagy were detected in dominant GARS mutations. The role of VAPB has been supported by similar results in the GarsC210R mice. Our data suggest that altered mitochondria-associated endoplasmic reticulum (ER) membranes (MAM) may be important disease mechanisms leading to neuropathy in this condition., R.H. is a Wellcome Investigator (109915/Z/15/Z) supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548) and the Mitochondrial European Educational Training (MEET), ITN MARIE CURIE PEOPLE, (317433). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement No. 305444 (RD-Connect), 305121 (Neuromics), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). H.J.G., A.R. and R.P.Z. acknowledge the financial support by the Ministeriumfür Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the SenatsverwaltungfürWirtschaft, Technologie und Forschung des Landes Berlin, and the BundesministeriumfürBildung und Forschung. H.G.J. further thanks the CAPES Foundation for financial support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GNE myopathy: from clinics and genetics to pathology and research strategies

  • Pogoryelova, Oksana
  • González Coraspe, José Andrés
  • Nikolenko, Nikoletta
  • Lochmüller, Hanns
  • Roos, Andreas
GNE myopathy is an ultra-rare autosomal recessive disease, which starts as a distal muscle weakness and ultimately leads to a wheelchair bound state. Molecular research and animal modelling significantly moved forward understanding of GNE myopathy mechanisms and suggested therapeutic interventions to alleviate the symptoms. Multiple therapeutic attempts are being made to supplement sialic acid depleted in GNE myopathy muscle cells. Translational research field provided valuable knowledge through natural history studies, patient registries and clinical trial, which significantly contributed to bringing forward an era of GNE myopathy treatment. In this review, we are summarising current GNE myopathy, scientific trends and open questions, which would be of significant interest for a wide neuromuscular diseases community., We gratefully acknowledge the financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen. Work by the authors has been supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444 (RD-Connect) and 305121 (NeurOmics). This work was further supported by a grant from the DGM (Deutsche Gesellschaft für Muskelkranke).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo PTEN mutation

  • Bansagi, Boglarka
  • Phan, Vietxuan
  • Baker, Mark R.
  • O&apos;Sullivan, Julia
  • Jennings, Matthew J.
  • Whittaker, Roger G.
  • Müller, Juliane
  • Duff, Jennifer
  • Griffin, Helen
  • Miller, James A.L.
  • Gorman, Grainne S.
  • Lochmüller, Hanns
  • Chinnery, Patrick F.
  • Roos, Andreas
  • Swan, Laura E.
  • Horvath, Rita
Objective: To describe a patient with a multifocal demyelinating motor neuropathy with onset in childhood and a mutation in phosphatase and tensin homolog (PTEN), a tumor suppressor gene associated with inherited tumor susceptibility conditions, macrocephaly, autism, ataxia, tremor, and epilepsy. Functional implications of this protein have been investigated in Parkinson and Alzheimer diseases. Methods: We performed whole-exome sequencing in the patient's genomic DNA validated by Sanger sequencing. Immunoblotting, in vitro enzymatic assay, and label-free shotgun proteomic profiling were performed in the patient's fibroblasts. Results: The predominant clinical presentation of the patient was a childhood onset, asymmetric progressive multifocal motor neuropathy. In addition, he presented with macrocephaly, autism spectrum disorder, and skin hamartomas, considered as clinical criteria for PTEN-related hamartoma tumor syndrome. Extensive tumor screening did not detect any malignancies. We detected a novel de novo heterozygous c.269T>C, p.(Phe90Ser) PTEN variant, which was absent in both parents. The pathogenicity of the variant is supported by altered expression of several PTEN-associated proteins involved in tumorigenesis. Moreover, fibroblasts showed a defect in catalytic activity of PTEN against the secondary substrate, phosphatidylinositol 3,4-trisphosphate. In support of our findings, focal hypermyelination leading to peripheral neuropathy has been reported in PTEN-deficient mice. Conclusion: We describe a novel phenotype, PTEN-associated multifocal demyelinating motor neuropathy with a skin hamartoma syndrome. A similar mechanism may potentially underlie other forms of Charcot-Marie-Tooth disease with involvement of the phosphatidylinositol pathway., R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK) (MR/N025431/1), and the European Research Council (309548). H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 305444 (RD-Connect) and 305121 (Neuromics), from the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and from the Newton Fund (UK/Turkey, MR/N027302/1). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Medical Research Council (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. A.R. received financial support from the Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen, the Senatsverwaltung für Wirtschaft, Technologie und Forschung des Landes Berlin and the Bundesministerium für Bildung und Forschung. L.E.S. was supported by Wellcome Trust (105616/Z/14/Z) and the Medical Research Council (MRC/N010035/1).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders

  • Salpietro, Vincenzo
  • Dixon, Christine L.
  • Guo, Hui
  • Bello, Oscar D.|||0000-0001-5701-8365
  • Vandrovcova, Jana
  • Efthymiou, Stephanie|||0000-0003-4900-9877
  • Maroofian, Reza
  • Heimer, Gali
  • Burglen, Lydie|||0000-0002-1119-6809
  • Valence, Stephanie|||0000-0003-4530-4537
  • Torti, Erin|||0000-0001-5790-1051
  • Hacke, Moritz
  • Rankin, Julia
  • Tariq, Huma|||0000-0002-4351-0241
  • Colin, Estelle
  • Procaccio, Vincent
  • Striano, Pasquale|||0000-0002-6065-1476
  • Mankad, Kshitij
  • Lieb, Andreas|||0000-0001-9567-649X
  • Chen, Sharon
  • Pisani, Laura
  • Bettencourt, Conceição|||0000-0001-9090-7690
  • Männikkö, Roope|||0000-0002-8727-9184
  • Manole, Andreea
  • Brusco, Alfredo|||0000-0002-8318-7231
  • Grosso, Enrico
  • Ferrero, Giovanni Battista|||0000-0002-3793-5788
  • Armstrong, Judith|||0000-0003-0588-9307
  • Gueden, Sophie
  • Bar-Yosef, Omer
  • Tzadok, Michal
  • Monaghan, Kristin G.
  • Santiago-Sim, Teresa
  • Person, Richard E.
  • Cho, Megan T.
  • Willaert, Rebecca
  • Yoo, Kristin
  • Chae, Jong-Hee
  • Quan, Yingting
  • Wu, Huidan
  • Wang, Tianyun
  • Bernier, Raphael A.
  • Xia, Kun
  • Blesson, Alyssa
  • Jain, Mahim
  • Motazacker, Mohammad M.
  • Jaeger, Bregje
  • Schneider, Amy L.|||0000-0001-5260-7187
  • Boysen, Katja|||0000-0002-4444-2797
  • Muir, Alison M.|||0000-0002-9420-085X
  • Myers, Candance T.
  • Gavrilova, Ralitza H.
  • Gunderson, Lauren
  • Schultz-Rogers, Laura|||0000-0002-7222-9985
  • Klee, Eric W.
  • Dyment, David
  • Osmond, Matthew
  • Parellada, Mara|||0000-0001-7977-3601
  • Llorente, Cloe
  • González-Peñas, Javier|||0000-0002-3850-3012
  • Carracedo, Ángel|||0000-0003-1085-8986
  • van Haeringen, Arie
  • Ruivenkamp, Claudia A.L.
  • Nava, Caroline|||0000-0003-1272-0518
  • Heron, Delphine
  • Nardello, Rosaria
  • Iacomino, Michele|||0000-0003-4788-9719
  • Minetti, Carlo|||0000-0002-0640-1804
  • Skabar, Aldo|||0000-0003-3034-8203
  • Fabretto, Antonella
  • Hanna, Michael|||0000-0003-0825-4075
  • Bugiardini, Enrico|||0000-0002-9709-6699
  • Hostettler, Isabel Charlotte|||0000-0002-9004-2540
  • O'Callaghan, Benjamin
  • Khan, Alaa
  • Cortese, Andrea
  • O'Connor, Emer
  • Yau, Wai Y.
  • Bourinaris, Thomas
  • Kaiyrzhanov, Rauan|||0000-0003-1640-4010
  • Chelban, Viorica|||0000-0002-5817-6290
  • Madej, Monika
  • Diana, Maria C.
  • Vari, Maria S.
  • Pedemonte, Marina|||0000-0001-8410-6918
  • Bruno, Claudio
  • Balagura, Ganna|||0000-0003-0212-8318
  • Scala, Marcello|||0000-0003-2194-7239
  • Fiorillo, Chiara|||0000-0001-9027-343X
  • Nobili, Lino|||0000-0001-9317-5405
  • Malintan, Nancy T.
  • Zanetti, Maria N.|||0000-0002-3992-7167
  • Krishnakumar, Shyam S.
  • Lignani, Gabriele|||0000-0002-3963-9296
  • Jepson, James E. C.
  • Broda, Paolo|||0000-0002-4178-1128
  • Baldassari, Simona|||0000-0002-5304-3608
  • Rossi, Pia
  • Fruscione, Floriana|||0000-0002-4054-645X
  • Madia, Francesca|||0000-0002-7807-1322
  • Traverso, Monica|||0000-0003-0606-8797
  • De-Marco, Patrizia|||0000-0001-8498-3750
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Munell Casadesus, Francina|||0000-0001-8580-2819
  • Kriouile, Yamna
  • El-Khorassani, Mohamed
  • Karashova, Blagovesta
  • Avdjieva, Daniela
  • Kathom, Hadil
  • Tincheva, Radka
  • Van-Maldergem, Lionel|||0000-0001-8880-5214
  • Nachbauer, Wolfgang
  • Boesch, Sylvia|||0000-0003-1657-7368
  • Gagliano, Antonella
  • Amadori, Elisabetta
  • Goraya, Jatinder S.
  • Sultan, Tipu
  • Kirmani, Salman
  • Ibrahim, Shahnaz
  • Jan, Farida
  • Mine, Jun
  • Banu, Selina
  • Veggiotti, Pierangelo|||0000-0003-2851-3441
  • Zuccotti, Gian V.
  • Ferrari, Michel D.|||0000-0001-9691-9449
  • Van Den Maagdenberg, Arn M. J.
  • Verrotti, Alberto
  • Marseglia, Gian Luigi|||0000-0003-3662-0159
  • Savasta, Salvatore
  • Soler, Miguel A.|||0000-0002-5780-9949
  • Scuderi, Carmela|||0000-0001-5901-0041
  • Borgione, Eugenia|||0000-0001-5458-7415
  • Chimenz, Roberto
  • Gitto, Eloisa|||0000-0001-7442-8630
  • Dipasquale, Valeria|||0000-0003-3328-0734
  • Sallemi, Alessia
  • Fusco, Monica
  • Cuppari, Caterina
  • Cutrupi, Maria C.
  • Ruggieri, Martino
  • Cama, Armando
  • Capra, Valeria|||0000-0002-3097-0388
  • Mencacci, Niccolò Emanuele|||0000-0003-3383-9665
  • Boles, Richard
  • Gupta, Neerja
  • Kabra, Madhulika
  • Papacostas, Savvas|||0000-0003-3845-7439
  • Zamba-Papanicolaou, Eleni
  • Dardiotis, Efthimios|||0000-0003-2957-641X
  • Maqbool, Shazia
  • Rana, Nuzhat
  • Atawneh, Osama
  • Lim, Shen Y.
  • Shaikh, Mohmad Farooq|||0000-0001-9865-6224
  • Koutsis, George|||0000-0002-8980-8377
  • Breza, Marianthi|||0000-0001-9213-7941
  • Coviello, Domenico|||0000-0001-8440-865X
  • Dauvilliers, Yves|||0000-0003-0683-6506
  • AlKhawaja, Issam
  • AlKhawaja, Mariam
  • Al-Mutairi, Fuad
  • Stojkovic, Tanya|||0000-0002-4054-2838
  • Ferrucci, Veronica|||0000-0002-2019-6501
  • Zollo, Massimo|||0000-0002-0970-7243
  • Alkuraya, Fowzan S.|||0000-0003-4158-341X
  • Kinali, Maria
  • Sherifa, Hamed
  • Benrhouma, Hanene
  • Turki, Ilhem B. Y.
  • Tazir, Meriem
  • Obeid, Makram|||0000-0003-4349-674X
  • Bakhtadze, Sophia|||0000-0003-4862-4026
  • Saadi, Marianthi W.
  • Zaki, Maha|||0000-0001-7840-0002
  • Triki, Chahnez C.
  • Benfenati, Fabio
  • Gustincich, Stefano|||0000-0002-2749-2514
  • Kara, Majdi
  • Belcastro, Vincenzo
  • Specchio, Nicola|||0000-0002-8120-0287
  • Capovilla, Giuseppe
  • Karimiani, Ehsan G.
  • Salih, Ahmed M.
  • Okubadejo, Njideka|||0000-0003-2975-8803
  • Ojo, Oluwadamilola|||0000-0001-6461-2653
  • Oshinaike, Olajumoke O.
  • Oguntunde, Olapeju
  • Wahab, Kolawole Wasiu|||0000-0002-2914-1953
  • Bello, Abiodun H.
  • Abubakar, Sanni
  • Obiabo, Yahaya
  • Nwazor, Ernest
  • Ekenze, Oluchi
  • Williams, Uduak|||0000-0001-7120-2572
  • Iyagba, Alagoma
  • Taiwo, Lolade
  • Komolafe, Morenikeji|||0000-0002-0592-5120
  • Senkevich, Konstantin|||0000-0003-3407-5716
  • Shashkin, Chingiz
  • Zharkynbekova, Nazira
  • Koneyev, Kairgali
  • Manizha, Ganieva
  • Isrofilov, Maksud
  • Guliyeva, Ulviyya|||0000-0003-3834-336X
  • Salayev, Kamran
  • Khachatryan, Samson G.|||0000-0002-3098-2135
  • Rossi, Salvatore|||0000-0002-7102-9180
  • Silvestri, Gabriella|||0000-0002-1950-1468
  • Haridy, Nourelhoda A.|||0000-0001-6045-3309
  • Ramenghi, Luca A.|||0000-0003-0065-762X
  • Xiromerisiou, Georgia|||0000-0001-7162-3588
  • David, Emanuele
  • Aguennouz, M'hammed|||0000-0003-0440-0354
  • Fidani, Lliana
  • Spanaki, Cleanthe
  • Tucci, Arianna|||0000-0001-5644-0070
  • Raspall-Chaure, Miquel|||0000-0002-3132-3342
  • Chez, Michael
  • Tsai, Anne
  • Fassi, Emily
  • Shinawi, Marwan|||0000-0003-1329-4100
  • Constantino, John N.
  • De Zorzi, Rita|||0000-0001-7001-7498
  • Fortuna, Sara|||0000-0002-8059-6064
  • Kok, Fernando
  • Keren, Boris
  • Bonneau, Dominique
  • Choi, Murim|||0000-0002-9195-1455
  • Benzeev, Bruria
  • Zara, Federico|||0000-0001-9744-5222
  • Mefford, Heather C.|||0000-0001-7188-522X
  • Scheffer, Ingrid E.
  • Clayton-Smith, Jill
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Rothman, James E.
  • Eichler, Evan E.|||0000-0002-8246-4014
  • Kullmann, Dimitri M.|||0000-0001-6696-3545
  • Houlden, Henry|||0000-0002-2866-7777
AMPA receptors (AMPARs) are tetrameric ligand-gated channels made up of combinations of GluA1-4 subunits encoded by GRIA1-4 genes. GluA2 has an especially important role because, following post-transcriptional editing at the Q607 site, it renders heteromultimeric AMPARs Ca-impermeable, with a linear relationship between current and trans-membrane voltage. Here, we report heterozygous de novo GRIA2 mutations in 28 unrelated patients with intellectual disability (ID) and neurodevelopmental abnormalities including autism spectrum disorder (ASD), Rett syndrome-like features, and seizures or developmental epileptic encephalopathy (DEE). In functional expression studies, mutations lead to a decrease in agonist-evoked current mediated by mutant subunits compared to wild-type channels. When GluA2 subunits are co-expressed with GluA1, most GRIA2 mutations cause a decreased current amplitude and some also affect voltage rectification. Our results show that de-novo variants in GRIA2 can cause neurodevelopmental disorders, complementing evidence that other genetic causes of ID, ASD and DEE also disrupt glutamatergic synaptic transmission.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Alternative splicing expands the clinical spectrum of ndufs6-related mitochondrial disorders

  • Armirola Ricaurte, C.
  • Zonnekein, N.
  • Koutsis, G.
  • Morís de la Tassa, Germán|||0000-0001-7608-2194
The European Community’s Seventh Framework Programme (FP7/ 2007-2013) under grant agreement n◦ 2012-305121 “Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)” and CMMC (C18) to B.W., a CMMC clinical scientist award to M.K., the Carlos III Health Institute (ISCIII) (Grant PI21/00103 to C.E.), the European Union—European Regional Development Fund and the European Social Fund (FSE) “A way of making Europe.” This research was funded in part, by the Wellcome Trust (WT093205MA, WT104033AIA). This study makes use of data shared/provided through RDConnect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 779257 (Solve-RD)., Armirola-Ricaurte C., Zonnekein N., Koutsis G., Amor-Barris S., Pelayo-Negro A.L., Atkinson D., Efthymiou S., Turchetti V., Dinopoulos A., Garcia A., Karakaya M., Moris G., Polat A.I., Yiş U., Espinos C., Van de Vondel L., De Vriendt E., Karadima G., Wirth B., Hanna M., Houlden H., Berciano J., Jordanova A.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The RD-connect genome-phenome analysis platform: accelerating diagnosis, research, and gene discovery for rare diseases

  • Laurie, Steven
  • Piscia, Davide
  • Matalonga, Leslie
  • Corvó, Alberto
  • Fernández-Callejo, Marcos
  • Garcia-Linares, Carles
  • Hernandez-Ferrer, Carles
  • Luengo, Cristina
  • Martínez, Inés
  • Papakonstantinou, Anastasios
  • Picó-Amador, Daniel
  • Protasio, Joan
  • Thompson, Rachel
  • Tonda, Raúl
  • Bayés, Mónica
  • Bullich, Gemma
  • Camps-Puchadas, Jordi
  • Paramonov, Ida
  • Trotta, Jean Remí
  • Alonso Sánchez, Ángel Miguel
  • Attimonelli, Marcella
  • Béroud, Christophe
  • Bros-Facer, Virginie
  • Buske, Orion J.
  • Cañada-Pallarés, Andrés
  • Fernández, José M.
  • Hansson, Mats G.
  • Horvath, Rita
  • Jacobsen, Julius O. B.
  • Kaliyaperumal, Rajaram
  • Lair-Préterre, Séverine
  • Licata, Luana
  • Lopes, Pedro
  • López-Martín, Estrella
  • Mascalzoni, Deborah
  • Monaco, Lucia
  • Pérez-Jurado, Luis A.
  • Posada-de-la-Paz, Manuel
  • Rambla, Jordi
  • Rath, Ana
  • Riess, Olaf
  • Robinson, Peter N.
  • Salgado, David
  • Smedley, Damian
  • Spalding, Dylan
  • &apos;t Hoen, Peter A. C.
  • Töpf, Ana
  • Zaharieva, Irina
  • Graessner, Holm
  • Gut, Ivo Glynne
  • Lochmüller, Hanns
  • Beltrán, Sergi
Rare disease patients are more likely to receive a rapid molecular diagnosis nowadays thanks to the wide adoption of next-generation sequencing. However, many cases remain undiagnosed even after exome or genome analysis, because the methods used missed the molecular cause in a known gene, or a novel causative gene could not be identified and/or confirmed. To address these challenges, the RD-Connect Genome-Phenome Analysis Platform (GPAP) facilitates the collation, discovery, sharing, and analysis of standardized genome-phenome data within a collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw genomic data which is processed through a standardized pipeline. After an optional embargo period, the data are shared with other platform users, with the objective that similar cases in the system and queries from peers may help diagnose the case. Additionally, the platform enables bidirectional discovery of similar cases in other databases from the Matchmaker Exchange network. To facilitate genome-phenome analysis and interpretation by clinical researchers, the RD-Connect GPAP provides a powerful user-friendly interface and leverages tens of information sources. As a result, the resource has already helped diagnose hundreds of rare disease patients and discover new disease causing genes., RD-Connect (RD-Connect, an integrated platform connecting registries, biobanks, and clinical bioinformatics) received funding from the Seventh Framework (FP7) Programme of the European Union under grant agreement No 305444. Data were analyzed using the RD-Connect GPAP, which received funding from EU projects Solve-RD, EJP-RD (grant numbers H2020 779257, H2020 825575), Instituto de Salud Carlos III (Grant numbers PT13/0001/0044, PT17/0009/0019; Instituto Nacional de Bioinformática, INB), ELIXIR-EXCELERATE (Grant number EU H2020 #676559) and ELIXIR Implementation Studies (Remote real-time visualization of human rare disease genomics data (RD-Connect) stored at the EGA ELIXIR. 2017-2018; ELIXIR IT-2017-INTEGRATION, Rare Disease Infrastructure ELIXIR, 2019-2020 and the Beacon ELIXIR, 2019-2021). The RD-Connect GPAP has leveraged developments funded through project VEIS (001-P-001647 co-financed by the European Regional Development Fund of the European Union in the framework of the Operational Program FEDER of Catalonia 2014-2020 with the support of the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya) and URD-Cat (PERIS SLT002/16/00174, Departament de Salut, Generalitat de Catalunya). The research leading to these results has received funding from Consequitur (Newton Fund UK/Turkey, MR/N027302/1), BBMRI-LPC (EU FP7 #313010), NeurOmics (EU FP7 #305121), the Economic Development Department of the Navarra Government (Grant number 001114112017), the European Reference Network for Rare Neurological Diseases (Project ID number 739510) and NIH, National Institute of Child Health and Human Development (1R01HD103805-01). We acknowledge the support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Generalitat de Catalunya through Departament de Salut and Departament d'Empresa i Coneixement and Co-financing by the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) with funds from the European Regional Development Fund (ERDF) corresponding to the 2014-2020 Smart Growth Operating Program. HL receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279).